Filing Flows › Beta Bionics (BBNX) › Q3 2026
Beta Bionics (BBNX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 27, 2026
Beta Bionics (BBNX) reported revenue of $35.5M for the third quarter 2026 (Q3 2026), +30% from a year earlier and +11% from the quarter before. Operating margin was -74.9%, net loss $24.4M (68.6% of revenue).
Beta Bionics, Q3 2026: revenue $35.5M (+30% year over year), operating margin -74.9%, net loss $24.4M, operating cash flow −$12.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $35.5M | +11% | +30% |
| Operating profit | −$26.6M | — | — |
| Net earnings | −$24.4M | — | — |
| Operating cash flow | −$12.3M | — | — |
What changed
Revenue was $35.5M in Q3 2026, up 30% year over year and up 11% from the previous quarter.
Gross margin was 57.3%, up 1.8 points from Q3 2025. Operating costs exceeded revenue by $26.6M, an operating margin of -74.9%. Operating expenses grew 46% against revenue growth of 30%. The fastest-growing cost line was Sales & marketing (+57%). The quarter ended with a net loss of $24.4M, wider than the previous quarter's $23.4M loss.
Operating cash flow was −$12.3M. Non-cash charges added back $892K of depreciation and $6.7M of share-based compensation. Working capital and other items added $4.5M. Capital expenditures of $2.3M exceeded it, leaving free cash flow of −$14.6M.
Questions
What was Beta Bionics' revenue in the third quarter 2026?
Beta Bionics (BBNX) reported revenue of $35.5M for the third quarter 2026 (Q3 2026), +30% from a year earlier and +11% from the quarter before.
Was Beta Bionics profitable in the third quarter 2026?
Operating loss was $26.6M (-74.9% of revenue) and net loss $24.4M.
Source: Beta Bionics 10-Q on SEC EDGAR.